eligibility_summary
Eligibility: Newly diagnosed CD20+ large cell lymphoma, anthracycline/cytotoxic-ineligible (≥80y or ≥75y with comorbidities), ICE ≥8, Ann Arbor II–IV, ECOG 0–2 (3 if improves ≤2 after pre-phase), measurable disease, adequate organ function, biopsy available. Exclude: active infections (incl COVID, HBV/HCV, CMV, TB), alcohol abuse/cirrhosis, severe CV disease, recent disallowed tx/surgery/transplants/vaccines/devices, CNS disease or seizures, other cancers, drug allergies, HIV+.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05660967: Open-label, randomized, global phase 2 in newly diagnosed, anthracycline-ineligible DLBCL. Interventions: (1) Epcoritamab (EPKINLY, GEN3013), a subcutaneous bispecific T‑cell–engaging antibody (BiAb) that binds CD3 on T cells and CD20 on B cells, redirecting T cells to lyse malignant B cells. (2) Epcoritamab plus lenalidomide (Revlimid), an oral immunomodulatory drug (IMiD). Mechanisms: Epcoritamab forms an immune synapse between CD3+ T cells and CD20+ lymphoma cells, triggering T-cell activation and cytotoxic killing. Lenalidomide binds cereblon to degrade IKZF1/3 (Ikaros/Aiolos), boosting T- and NK-cell function, IL‑2/cytokine production, and exerting anti-angiogenic effects. Targets/pathways: CD20+ B cells, CD3+ T-cell activation, cereblon E3 ligase–IKZF1/3 axis, tumor microenvironment and angiogenesis.